Concerta (Extended‑Release Methylphenidate) Clinical Guideline Summary

Titration and Monitoring

The titration phase usually lasts 2–4 weeks, with weekly contact (including telephone) to assess response and side effects, using parent and teacher reports plus standardized rating scales. American Academy of Child and Adolescent Psychiatry recommends this schedule. 1
Cardiovascular monitoring is required: measure blood pressure and pulse at baseline and each dose adjustment. 1

The 12‑hour delivery of Concerta eliminates the need for school‑based dosing, enhancing privacy and adherence for school‑aged patients. American Academy of Child and Adolescent Psychiatry notes this benefit. 2

Appetite suppression and weight loss are frequent; clinicians should weigh patients at each visit. 1
Insomnia may occur; scheduling the dose early in the day can mitigate this effect. Evidence reported by both the American Academy of Child and Adolescent Psychiatry and the National Comprehensive Cancer Network. [1][3]
Agitation, headaches, and social withdrawal are also observed adverse events. 1
Cardiovascular effects such as increased heart rate and blood pressure may develop and should be monitored. 1

Preschool children (4–5 years): Concerta is not FDA‑approved for this age group. When severe ADHD is refractory to behavioral therapy, clinicians should consider immediate‑release methylphenidate at lower starting doses due to slower metabolism. Pediatrics guideline. 4
Adolescents: The once‑daily, tamper‑resistant formulation reduces diversion risk and removes the need for school dosing. American Academy of Child and Adolescent Psychiatry recommends this approach. 2
Adolescents also require coverage for evening activities (e.g., driving) because ADHD increases crash risk. Pediatrics guideline. 4
Adults: Prior to prescribing, screen for a history of substance use because stimulants have abuse potential. Pediatrics guideline. 4

Concerta delivers ascending plasma concentrations (≈ 22 % immediate‑release overcoat plus osmotic pump) designed to overcome acute tolerance and sustain efficacy throughout the 12‑hour period. American Academy of Child and Adolescent Psychiatry describes this pharmacokinetic profile. 5
This formulation is superior to older sustained‑release preparations (e.g., MPH‑SR20), which have delayed onset and lower peak concentrations. Evidence from the American Academy of Child and Adolescent Psychiatry. 5